EyePoint Completes Enrollment in Phase 3 DME Trials

More than 480 patients have joined the COMO and CAPRI studies evaluating six-month dosing of EyePoint’s investigational retinal therapy, DURAVYU

1

EyePoint has completed enrollment in two pivotal Phase 3 trials for DURAVYU, a treatment for diabetic macular edema.
2

The COMO and CAPRI studies enrolled over 480 patients in five months, achieving full enrollment ahead of schedule.
3

DURAVYU is designed to release treatment for at least six months and combines vorolanib with Durasert E technology.
4

The primary endpoint of the trials will assess non-inferiority to aflibercept in best-corrected visual acuity changes.
5

DURAVYU targets multiple biological drivers of DME, including VEGF receptors and inflammation through IL-6/JAK1 signaling.

1